Acquisition Opportunity The Dunn Group was acquired by SAI MedPartners in December 2025, signaling a potential transition in client base and integration opportunities for productized competitive intelligence services, data enrichment offerings, or expanded BI capabilities within a larger portfolio.

Scale Potential With a revenue range of 10M to 25M and a small team (11-50 employees), TDG may be open to scalable, cloud-based intelligence platforms, managed services, and tiered consulting engagements that deliver rapid ROI and predictable pricing as a growth partner.

Pharma BI Niche TDG focuses on competitive intelligence for life sciences including pharmaceuticals, biotech, diagnostics, and medical devices. This presents opportunities to cross-sell data analytics, market trend reports, supplier risk monitoring, and regulatory intelligence services to similar buyers in larger pharma and medtech firms.

Tech Stack Fit Current technology usage (Google Cloud, Wix/WordPress, Microsoft 365, Sentry) indicates openness to cloud-native BI tools, data pipelines, and secure web portals. Propose integrations or enhancements with telemetry, dashboards, and client-facing portals tailored for life sciences customers.

Growth Readiness Recent news of acquisition and a mid-market revenue profile suggest readiness for strategic partnerships, channel partnerships, or co-sell arrangements with large health sciences consultancies or CROs seeking to augment competitive intelligence capabilities.